Alzheimer's Disease International (ADI)
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
Lecanemab is the first therapy of its kind approved in the EU that could potentially slow the progression of Alzheimer’s disease. The use of lecanemab will now be considered by national payers, who will assess the treatment against further nationally determined criteria.
This comes as the Appeals board of the European Commission were unable to reach a verdict following the “no opinion” decision of the Standing Committee on Medicinal Products for Human Use and the European Commission. The matter will now be referred the European Commission for a final decision.
Since 2021, Alzheimer’s Society of Maldives has worked tirelessly to address the needs of people with dementia and their carers. Through advocacy, collaboration with ADI, and engagement with the Maldivian government, the organisation is playing a key role in the development of the Maldives’ first National Dementia Plan, which is set for launch this year. This milestone highlights the impact of coordinated efforts to improve dementia care in the country.
ADI, in collaboration with academics from the London School of Economics, published a commentary in Nature Reviews Neurology urging governments to include dementia in NCD policies and frameworks. This paper reveals striking data, including dementia becoming the 3rd leading cause of death globally by 2040 and among the top 10 causes of death in 166 countries.
As we come to the end of 2024, CEO Paola Barbarino shares a message with our members, friends, and colleagues, to summarise our activities in 2024 and to give a preview of what we, at ADI, are looking forward to in 2025. Throughout this year, ADI has continued to raise global awareness of dementia, of the challenges and difficulties that families around the world face every day, but also of the hope that new research and emerging treatments bring to us.
On 10 December, ADI launched its inaugural End of Year Forecast, focusing on ‘Translating the Alzheimer's Treatment Revolution into Real World Solutions’. This event sought to highlight the new era for Alzheimer’s treatments and cut through the often confusing and cryptic information that is available to the general public. ADI is pleased to share the slide featured in this event. Make sure to scroll down the page to see all 127 Alzheimer’s treatments and their place in the pipeline.
In November 2024, ADI saw dementia action take place across Latin America. Regional Director, Diego Aguilar participated in Brain Week in Santa Cruz de la Sierra, Bolivia, organised by Asociación Alzheimer Bolivia (AAB) and Alzheimer Iberoamérica. Meanwhile, the Government of Tucumán, Argentina, launched the country’s first subnational dementia plan, thanks to years of advocacy by ADI, ALMA, and Fundación León.
As the number of Alzheimer’s treatments seeking regulatory approval rises, ADI continues to provide technical and patient-centred guidance to regulators. In this blog, ADI highlights some of our ongoing engagement in this area, based on our guiding principles in this area:
In November, ADI highlighted key updates from Belgium, including the first Flanders conference on dementia risk reduction and the recognition of the ennoblement of Sabine Henry for her contributions to dementia advocacy.
This month, ADI’s Head of Accreditation, Amalia Fonk-Utomo, visited Singapore for an impactful trip where she explored key opportunities for improving dementia care, promoted the ADI Accreditation program, and built collaborative partnerships across the region.